NEWS RELEASE

Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting

9/27/2023

LARKSPUR, Calif.--(BUSINESS WIRE)-- Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that new safety and efficacy data from the Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. AU-007 is a human IgG1 monoclonal antibody designed using artificial intelligence to harness the power of interleukin-2 (IL-2) to eradicate solid tumors. The SITC meeting is being held virtually and in San Diego, California, from November 1-5, 2023.

“Using artificial intelligence, AU-007 is designed to bind to IL-2 precisely instead of the IL-2 receptor. The result is a novel mechanism of action showing early promise in overcoming long-standing challenges for IL-2 therapies,” said **Aron Knickerbocker, Aulos Bioscience’s chief executive officer**. “As patient enrollment continues at multiple study locations in the United States and Australia, we look forward to presenting updated safety and efficacy data from the Phase 1 portion of the study at the SITC Annual Meeting.”

Details of the poster presentation are as follows:

Poster Title: A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results from dose escalation

Abstract: 717

Date and Time: Friday, November 3, 2023, 9:00 a.m.-7:00 p.m. PDT

The poster will be presented in the Poster Hall, Exhibit Halls A and B1 at the San Diego Convention Center. It will also be available as an ePoster on display on the SITC 2023 virtual meeting platform.

About AU-007

AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. AU-007 also prevents IL-2 from binding to trimeric receptors on vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the AU-007 Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: **NCT05267626**), **www.solidtumorstudy.com** (U.S.) and **www.solidtumourstudy.com** (Australia).

About Aulos

Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through best-in-class IL-2 therapeutics that direct patients' immune systems toward killing tumor cells. Matching world-class machine learning from co-founder **Biolojic Design** with an in-depth understanding of the immune system, Aulos' initial clinical candidate, AU-007, is a computationally designed human antibody that harnesses the power of IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by Biolojic Design and **ATP**, and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit **www.aulosbio.com**, X (Twitter) at **@AulosBioscience** and **LinkedIn**.

Contact: **info@aulosbio.com**
Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961-2502 / **mikebeyer@sambrown.com**

Source: Aulos Bioscience